Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).

Haberkorn, Brigitte C M; Eskens, Ferry A L M

Haberkorn, Brigitte C M; Eskens, Ferry A L M.

Affiliation

Haberkorn BC; Erasmus University Medical Center & Daniel den Hoed Cancer Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands. b.haberkorn@erasmusmc.nl

Future Oncol ; 9(1): 13-20, 2013 Jan.

Article in En | MEDLINE | ID: mdl-23252559

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Antineoplastic Agents/therapeutic use; Carcinoma, Renal Cell/drug therapy; Kidney Neoplasms/drug therapy; Phenylurea Compounds/therapeutic use; Quinolines/therapeutic use; Angiogenesis Inhibitors/chemistry; Angiogenesis Inhibitors/pharmacology; Animals; Antineoplastic Agents/chemistry; Antineoplastic Agents/pharmacology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Phenylurea Compounds/chemistry; Phenylurea Compounds/pharmacology; Quinolines/chemistry; Quinolines/pharmacology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Phenylurea Compounds / Quinolines / Carcinoma, Renal Cell / Angiogenesis Inhibitors / Kidney Neoplasms / Antineoplastic Agents Limits: Animals / Humans Language: En Journal: Future Oncol Year: 2013 Type: Article Affiliation country: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google